BCOR, manufactures and markets analytical instruments that employ affinity-based biosensor technology used for monitoring biomolecular interactions as they occur and provide real-time information that describes the association and dissociation of biomolecules. For the six months ended 6/30/99, revenues rose 4% to SEK142.7 million. Net income fell 5% to SEK19.6 million. Revenues benefited from strong sales in Japan. Net income was offset by currency differences.
Book Value (mrq) $4.57
Earnings (ttm) $0.46
Earnings (mrq) $0.10
Sales (ttm) $3.47
Cash (mrq) $2.82
Q4 Highlights:
* Full-year sales increased by 18% to SEK 340 million after a very strong
fourth quarter.
* Earnings per share up 29% to SEK 5.26 (4.07).
* Major victory for Biacore in U.S. patent dispute.
* Strategic focus on drug discovery as a major growth opportunity. Key
collaboration agreements signed.
* Technology breakthrough opens new application areas.
* For the full-year 2000, a sales growth in the range of 10-15% is
expected.
Market cap under $200 million currently, key deal with MLNM in December:
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) today announced that it has entered into a collaborative agreement with Biacore International AB (Nasdaq: BCOR - news) under which Millennium will evaluate Biacore's latest instrumentation in drug-discovery applications. Biacore's new prototype instrument further enhances the affinity-based biosensor technology underlying all of its products, which enables detection of biomolecules and binding events in real time, without the use of labels. Millennium will utilize the improved biosensor technology to accelerate its identification of potential drug targets and of small molecules that interact with them. |
